Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Peter Zage, M.D., Ph.D.

Peter E. Zage, M.D., Ph.D. 

Peter E. Zage, M.D., Ph.D.

Peter E. Zage, M.D., Ph.D.

Assistant Member
The Methodist Hospital Research Institute
Assistant Professor, Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine
Member, Solid Tumor Team, Neuroblastoma Program
Developmental Therapeutics and Clinical Pharmacology Program
Texas Children's Hospital
Co-Director, Retinoblastoma Center of Houston
Member, Neuroscience Program
University of Texas Graduate School of Biomedical Sciences
 
Phone: 832-824-4615
Fax: 832-825-4039
Email: zage@bcm.edu, pezage@txccc.org


Education

B.A.   John Hopkins University (Biology)
M.D.   Columbia University College of Physicians & Surgeons
Ph.D.   Columbia University Graudate School of Arts and Sciences

Postdoctoral Training

Resident, University of chicago Children's Hospital (Pediatrics)

Fellow, Children's memorial Hospital, chicago, IL (Pediatric Hematology/ Oncology)

 

Biography

Dr. Zage graduated from The Johns Hopkins University in 1990 with a B.A. degree in biology and subsequently received his M.D. and Ph.D. degrees from Columbia University in New York. He completed a residency in pediatrics at the University of Chicago Children's Hospital, followed by a fellowship in pediatric hematology/oncology at the Children's Memorial Hospital in Chicago. During his fellowship, he developed an interest in the pathogenesis of pediatric solid tumors, particularly neuroblastoma and retinoblastoma. He was an Assistant Professor in the Division of Pediatrics at M. D. Anderson Cancer Center from 2006 to 2011, where he also served as a research co-director of the Retinoblastoma Center of Houston. He became a member of The Methodist Hospital Research Institute in 2008. In 2011, Dr. Zage accepted a position as an Assistant Professor at Baylor College of Medicine and as a member of the solid tumor and developmental therapeutics teams at Texas Children's Hospital.

Dr. Zage continues to serve as a co-director of the Retinoblastoma Center of Houston and is an adjunct member of the Neuroscience program at the University of Texas Graduate School of Biomedical Sciences. He was awarded the Young Investigator Award from the American Society of Pediatric Hematology/Oncology in 2009 for his research focused on novel therapies for children with solid tumors in general and neuroblastoma in particular.

Description of Research

Dr. Zage's laboratory is primarily interested in evaluating the efficacy of novel therapies for children with neuroblastoma, retinoblastoma and other childhood solid tumors and in understanding the critical genetic and molecular events that could be used as targets for new treatments. He is developing a comprehensive program for the treatment of children with recurrent or refractory neuroblastoma, including chemotherapy, novel biologically targeted agents and immunotherapy. he collaborateswith other institutions in the development of innovative approaches to treatments for all children with cancer.

Major Areas of Research

Neuroblastoma, retinoblastoma, developmental therapeutics

Recent Publications

Levy AG, Zage PE, Akers LJ, Ghisoli ML, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin AR, Huang P, Zweidler-McKay PA.The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Invest New Drugs. 2010 Oct 5. PMID: 20890785.

Zage PE, Graham TC, Zeng L, Fang W, Pien C, Thress K, Omer C, Brown JL, Zweidler-McKay PA. The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer. 2011 Mar 15;117(6):1321-91. PMID: 20960503

Das CM, Zage PE, Taylor P, Aguilera D, Wolff JE, Lee D, Gopalakrishnan V. Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. Eur J Cancer. 2010 Oct;46(15):2771-80.
PMID: 20886683.

Richards KN, Zweidler-McKay PA, Van Roy N, Speleman F, Trevino J, Zage PE, Hughes DP. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer. 2010 Jul 1;116(13):3233-43. PMID: 20564646.

Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV. Multiple Receptor Tyrosine Kinases Regulate HIF-1a and HIF-2a in Normoxia and Hypoxia in Neuroblastoma: Implications for Antiangiogenic Mechanisms of Multikinase Inhibitors. Oncogene. 2010;29(20): 2938-49. PMID: 20208561

Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV, Zweidler-McKay PA. A Novel Therapeutic Combination for Neuroblastoma: the VEGFR/EGFR/RET Inhibitor Vandetanib with 13-cis-Retinoic Acid. Cancer. 2010;116(10): 2465-75. PMID: 20225331

Thress K, Macintyre T, Wang H, Whitston D, Liu ZY, Hoffmann E, Wang T, Brown JL, Webster K, Omer C, Zage PE, Zeng L, Zweidler-McKay PA. Identification and Preclinical Characterization of AZ-23, a Novel, Selective, and Orally Bioavailable Inhibitor of the Trk Kinase Pathway. Molecular Cancer Therapeutics. 2009;8(7): 1818-27. PMID 19509272

Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, London WB, Kretschmar C; Children's Oncology Group. Outcomes of the POG 9340/9341/9342 Trial for Children with High-Risk Neuroblastoma: a Report from the Children's Oncology Group. Pediatric Blood and Cancer. 2008;51(6): 747-53. PMID: 18704922

Zage PE, Reitman AJ, Seshadri R, Weinstein JL, Mets MB, Zeid JL, Greenwald MJ, Strauss LC, Goldman S. Outcomes of a Two-Drug Chemotherapy Regimen for Intraocular Retinoblastoma. Pediatric Blood and Cancer. 2008;50 (3): 567-72. PMID: 17729249

Links

Texas Children's Cancer Center profile
The Retinoblastoma Center of Houston profile